NL-OMON42040
Completed
N/A
Evaluation of 3'-deoxy-3'-[18F]fluorothymidine -PET and diffusion weighted imaging -MRI in patients with early stage non-small cell lung cancer treated with a platinum-based doublet as preoperative chemotherapy. - Preoperative PET and MR study in lung cancer patients
European Organisation for Research in Treatment of Cancer (EORTC)0 sites4 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Lungcancer
- Sponsor
- European Organisation for Research in Treatment of Cancer (EORTC)
- Enrollment
- 4
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* Age \>\= 18 years
- •\* WHO performance status 0\-1
- •\* Histologically or cytological confirmed clinical stage II\-IIIA non\-small cell lung carcinoma (NSCLC), according to 7th TNM classification (NOTE: patients with resectable N2 disease are also eligible)
- •\* Baseline standard imaging assessment \& staging should be performed within 6 weeks prior to planned treatment start.
- •\* Patients must be candidate for curative intent surgery, and must be expected to complete the treatment.
- •\* No prior or current anticancer treatment for NSCLC, pre\-operative therapy will include only chemotherapeutic drugs (pemetrexed is contraindicated), no other biological, targeted or radiotherapy is allowed
- •\* No treatment with any investigational drug substance within 4 weeks prior to registration.
- •\* No other malignancies in the 3 years prior to study entry with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, and basal/squamous cell carcinoma of the skin
- •\* No evidence of any medical condition which would impair the ability of the patient to participate in the trial or might preclude therapy with chemotherapeutic drugs according to routine medical practice (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease, known dihydropyrimidine dehydrogenase deficiency, active infection, uncontrolled diabetes mellitus; uncontrolled arterial hypertension, history of unstable myocardial infarction)
- •\* Adequate hematology and biochemical investigations, (should be done maximum 6 weeks before treatment starts)
Exclusion Criteria
- •\- Does not meet the inclusion criteria
- •\- Younger than 50 years
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Study of Clinical Usefulness of 18F-fluorothymidine(FLT) PET/CT in Ditection of Peritoneal Metastases of Gastric CancerJPRN-UMIN000009329Department of Gastrointestinal Oncology, National Cancer Center Hospital in Japan40
Not Yet Recruiting
N/A
Movember substudyNL-OMON26162VU university Medical Center10
Completed
Phase 2
Phase II study of 18 F fluorothymidine Positron Emission Tomography (FLT-PET) in the follow up of glioblastoma multiforme (GBM) patients treated with combined radiotherapie and chemotherapybraintumorglioblastoma multiforme10029211NL-OMON38320niversitair Medisch Centrum Groningen30
Completed
N/A
A study of usefulness of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the initial staging and assessment of response to treatment in locally advanced breast cancerHealth Condition 1: null- patients with locally advanced breast cancerCTRI/2018/04/013455Sri Venkateswara Institute of Medical Sciences
Unknown
N/A
Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative ChemoNon-small Cell Lung CarcinomaNCT02273271European Organisation for Research and Treatment of Cancer - EORTC31